US Supreme Court sides with Teva in drug dispute
Teva Pharmaceuticals gets a coronavirus boost, but it won't last long - Business - Haaretz.com
/cloudfront-us-east-2.images.arcpublishing.com/reuters/5OMAQFWFHNJDZCDZKKO5DWLBG4.jpg "Teva Israel enters medical cannabis market with new partnership | Reuters")
Teva Israel enters medical cannabis market with new partnership | Reuters
Teva CEO: Company would have gone bankrupt without layoffs - Business - Haaretz.com
Teva faces class-action lawsuit over US antitrust probe into price-fixing | The Times of Israel
Teva Pharm Q3 profit misses estimates, sees recovery into Q4 By Reuters
Teva tries to clear Allergan deal with $2B more in asset sales: Reuters | FiercePharma
Teva Pharm woes seen denting Israeli exports, economic growth By Reuters
Reuters report cited by Mylan executive chairman in letter to Teva CEO - Reuters News Agency
Teva shares tumble amid political battle, doubt from Moody's
Teva settles shareholder lawsuit over generic drug pricing for $420 million | Reuters.com
Teva says vaccine makers have not taken its offer to help produce jabs | Financial Times
Teva Pharm Expects About 25 Percent of EpiPen Market by Year End
Teva Pharmaceutical Industries Ltd | Reuters
Teva settles shareholder lawsuit over generic drug pricing for $420 million | Reuters.com
What's 'down' with Teva? - The Jerusalem Post
Outrage as Teva charges $18,275 for generic drug in US - The Jerusalem Post
Teva Pharmaceutical Industries Ltd | Reuters
Teva settles shareholder lawsuit over generic drug pricing for $420 million | Reuters.com
Teva Pharmaceuticals Slashing 25% of Workforce, Suspending Dividend
Teva Pharmaceutical Industries Ltd | Reuters
Teva Pharmaceuticals at heart of major price fixing suit in US - www.israelhayom.com
A Drug Company Wagers the U.S. Won't Dare Charge It With Crimes - The New York Times
California judge rules for Israeli Teva in major opioid lawsuit - The Jerusalem Post
/cloudfront-us-east-2.images.arcpublishing.com/reuters/ANJL4AXVTBOMDKS2X4DIJZXZAY.jpg "Teva loses bid to cancel Corcept drug patent at Federal Circuit | Reuters")